PRECISION MEDICINE DATA PLATFORM
bg-row1.jpg
YOUR PARTNER IN MOLECULAR AND REAL-WORLD EVIDENCE DATA FROM PATIENTS
FOR IMMUNOTHERAPIES
Our approach is based on transformative concept that leverages molecular and clinical RWE data and machine learning/AI and allows us to de-risk upfront theranostic development
OUR SERVICE
WHAT
WE DO
Asylia Diagnostics is focusing on the field of immunotherapies. We collect molecular and real-world evidence data from patients treated with investigational drugs in clinical trials and patients treated by the standard of care therapies. We’re building diverse datasets to unlock scientific discoveries as well as improve diagnostic and treatment outcomes
HOW
WE DO IT
OUR TECHNOLOGY
Our technology allows us to identify non-responders to SoC, dissect patient strata, find relevant biomarkers, and novel targets so we can feed our early pipeline of precision medicine solutions for patients.
Rectangle 152.jpg
01
COLLECT MOLECULAR
AND REAL-WORLD EVIDENCE DATA
We collect molecular and real-world evidence data from patients treated with investigational drugs in clinical trials and patients treated by the standard of care therapies.
02
TRANSFORM HETEROGENEOUS PATIENT POPULATION INTO SUBGROUPS
Discover well-defined subgroups that share common molecular and immuno-pathophysiology profiles using our proprietary ML-powered platform AsyliaAI™. By doing this we are able to identify highly specific biomarkers and novel drug targets.
03
DEVELOP PATIENT STRATIFICATION
AND INDICATION EXPANSION STRATEGIES
Use discovered endotypes, biomarkers, and drug targets to develop patient stratification, enrichment, and indication expansion strategies, early hits/leads for the therapeutic pipeline, and complex theranostic products together with our biopharma and IVD partners.
OUR AUDIENCE
Rectangle 150.jpg
Rectangle 149.jpg
row-4_3.jpg
SCALABLE AND PROVEN TECHNOLOGY PLATFORM FOR
CLINICAL ONCOLOGISTS
The first clinically validated product of Asylia is a molecular test for metastatic melanoma patients treated with immune checkpoint inhibitors (PD1/PD-L1) that allows for predicting the likelihood of adverse events post-treatment and patient response to therapy. This is the first-in-class tool for metastatic melanoma PD-1/L1 patient stratification that should enable treating oncologists with a more informed decision about mono or combo therapy options for stage III of melanoma.
BIOPHARMA
Identify commercial opportunities for indication expansion, novel targets, patient enrichment and stratification, that strengthen the clinical and commercial value proposition and enable precision medicine-driven theranostic development
STRONG IP
We have two filed PCTs with positive feedback on novelty and inventiveness and broad claims approved by the EPO and the IP strategy centered on building a battery of biomarkers and composition of matter patents targeting theranostics use cases.
bg-row6.jpg
STRONG 
TRACTION
  • PILOT WITH PHARMA
  • CO-DEVELOPMENT WITH IVD PARTNERS
  • CLINICAL TRIALS IN LEADING EUROPEAN HOSPITALS 
We have two filed PCTs with positive feedback on novelty and inventiveness and broad claims approved by the EPO and the IP strategy centered on building a battery of biomarkers and composition of matter patents targeting theranostics use cases.
MAKE RELEVANT
DATA AND PRECISION MEDICINE TOOLS TOGETHER
OUR INVESTORS AND PARTNERS
PARTNERSHIP
With our data science TECHNOLOGY, we are strongly positioned to partner with various organization types
BECOME
OUR PARTNER
Our technology is uniquely positioned to deliver transformative medicines faster and more efficiently. 
TECH/TECHXBIO INVESTOR
DO YOU WANT TO TAP INTO SOARING TREND OF BIO?
Asylia brings innovative AI-powered technology to the field of cancer immunotherapy and build a platform with deep data network effects
CONVENTIONAL BIOTECH INVESTOR
ARE YOU UNDERSTANDS THE VALUE OF PRECISION MEDICINE AND POWER OF MOLECULAR AND CLINICAL DATA?
Asylia has built and clinically validated its first patient stratification and enrichment tool for metastatic melanoma patients and ready for an LDT and IVD marking.
IVD COMPANY
DO YOU WANT TO EXPAND YOUR DIAGNOSTICS PORTFOLIO IN ONCOLOGY AUTOIMMUNE DISEASES?
Asylia has developed its first clinical product with a high unmet clinical need for melanoma cancers treated by PD-1/L1 checkpoint inhibitors and built a rich pipeline of diagnostics products for other use cases in skin cancers
BIOTECH/PHARMA COMPANY DEVELOPING NOVEL IMMUNE CHECKPOINT INHIBITORS
DO YOU NEED TO GROW MARKER SHARE IN THE COMPETITIVE MARKER?
Talk to us about patient stratification and enrichment collaborations as well as tap into our proprietary data pool of rich and well annotated molecular and clinical RWE data on patients treated by PD-1/L1 and CTLA4 inhibitors
Rectangle 152-1.jpg
LET’S COLLABORATE
OUR
MULTI-DISCIPLINARY SCIENTIFIC TEAM
ASYLIA FACES
Asylia has set up a multi-disciplinary scientific team uniquely positioned to deliver precision medicine tools thanks to a combination of technical, biological, and laboratory skills acquired
15+
YEARS OF EXPERIENCE IN RESEARCH
10+
YEARS IN DEVELOPMENT OF MOLEKULAR BIOLOGY
Andrej
ANDREY KHMELEVSKIY
The CEO, Co-Founder, Andrey Khmelevskiy, has over 15 years of experience as a manager and entrepreneur in the data sciences and bioinformatics field. He held executive roles at Saudi Aramco, InsideDNA, Exclusive Analysis, JP Kenny, Frecom and Wiltshire Council.
YOUR STRONG TEAM OF FOUNDERS-SCIENTISTS
AND ADVISOR
Anna
DR. ANNA KOSTIKOVA
Dr. Anna Kostikova, Co-Founder, has over 15 years of experience in managerial roles in pharma and multinational companies. She serves as a Director of Data Science at Novartis and led data science teams at Deloitte, InsideDNA, Booking.com and Heineken.
LET’S CONNECT OUR EXPERIENCE WITH YOUR NEEDS
CONTACT INFO
JLABS @ BE, Janssen Pharmaceutica NV Beerse Site 1, Turnhoutseweg 30, 2340 Beerse, Belgium.
WE ARE IN SOCIALS
  • LinkedIn
© Copyright 2019-2022 by ASYLIA.